**Exhibit
        31.1**
 
 **Certification
        of Principal Executive Officer and Principal Financial Officer**
 **Pursuant
        to Section 302 of the Sarbanes-Oxley Act of 2002**
 **and
        Securities and Exchange Commission Release 34-46427**
 
 I,
        Anna
        Kazanchyan, M.D., certify that:
 
 1.
        I have
        reviewed this quarterly report on Form 10-QSB of Heratsi Pharmaceuticals,
        Inc.;
 
 2.
        Based
        on my knowledge, this quarterly report does not contain any untrue statement
        of
        a material fact or omit to state a material fact necessary to make the
        statements made, in light of the circumstances under which such statements
        were
        made, not misleading with respect to the period covered by this quarterly
        report;
 
 3.
        Based
        on my knowledge, the financial statements, and other financial information
        included in this quarterly report, fairly present in all material respects
        the
        financial condition, results of operations and cash flows of the registrant
        as
        of, and for, the periods presented in this quarterly report;
 
 4.
        I am
        responsible for establishing and maintaining disclosure controls and procedures
        (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant
        and have:
 
 a)
        designed such disclosure controls and procedures or caused such disclosure
        controls and procedures to be designed under our supervision, to ensure that
        material information relating to the registrant, including its consolidated
        subsidiaries, is made known to us by others within those entities, particularly
        during the period in which this quarterly report is being prepared;
 
 b)
        evaluated the
        effectiveness of the small business issuer's disclosure controls and procedures
        and presented in this report our conclusions about the effectiveness of the
        disclosure controls and procedures, as of the end of the period covered by
        this
        report based on such evaluation;
 
 c)
        disclosed in this report any change in registrant’s internal control over
        financial reporting that occurred during the registrant’s most recent fiscal
        quarter that has materially affected, or is reasonably likely to materially
        affect, the registrant’s internal control over financial reporting;
        and
 
 5.
        I have
        disclosed, based on my most recent evaluation of internal control over financial
        reporting, to the registrant's auditors and the audit committee of registrant's
        board of directors (or persons performing the equivalent functions):
 
 a)
        all
        deficiencies and material weaknesses in the design or operation of internal
        control over financial reporting which are reasonably likely to adversely
        affect
        the registrant's ability to record, process, summarize and report financial
        information; and
 
 b)
        any
        fraud, whether or not material, that involves management or other employees
        who
        have a significant role in the registrant's internal control over financial
        reporting.
 
 Date:
                  August 13, 2007
              /s/
                  Anna Kazanchyan, M.D.
                Anna
                  Kazanchyan, M.D.
                Principal
                  Executive Officer
                Principal
                  Financial Officer